Abstract:e12600 Background: Noninvasive circulating cell-free DNA (cfDNA) detection has been applied to predict relapse and prognosis of breast cancer. However, most of studies were about pts with multi-lines treatment, and systematic evaluation of cfDNA from primary breast cancer (PBC) was still absent. This study aim to comprehensively assess the cfDNA detection and explore the factors affecting the release of tumor-derived variants in PBC pts. Methods: 71 females initially diagnosed with PBC were enrolled. Treatment-naive peripheral blood, and paired tumor tissue from surgical resection/fine-needle aspiration (FNA) were obtained. Target-capture deep sequencing with a panel covering 1021 genes was performed to detect somatic variants. Clonality of variants was analyzed using PyClone with Bayesian algorithm. Results: 226 somatic variants were detected in tumor DNA of 70 pts (98.59%), and 114 somatic variants were detected in cfDNA of 48 pts (67.61%). Significant correlation was found between mutant frequencies of genes in tumor DNA and cfDNA (R2 = 0.9532, p < 0.0001). 94 tumor-derived variants could be detected in cfDNA of 43 pts, and similar enrichment of functions and pathways for mutated genes was present in tumor specific and overlapped variants. TNM stage (p = 0.026), individual N stage (p < 0.001), hormone receptor (HR) status (p = 0.001) and molecular subtypes (p = 0.002) could independently predicted the positive detection of tumor-derived variants in cfDNA. The maximal variant allele frequency (MVAF) of cfDNA was significantly higher in pts with stage IV (p = 0.0136) and T3/T4 stage (p = 0.0085). Clonal variants in tumor DNA were much easier to be detected in cfDNA than subclonal variants (84.62% vs. 48.75%). Conclusions: Profiling tumor-derived variants in cfDNA is a promising method to assess mutational profile, and PBC pts with advanced stage and positive HR status are more likely to benefit from cfDNA sequencing. Clinical trial information: NCT02797652.

Clinical and Phylogenetic Factors Affecting the Detection of Genomic Variants in Circulating Cell-Free DNA for Patient with Primary Breast Cancer.